Government award will advance the company's non-vaccine influenza therapeutic, CD388, and onshore its manufacturing ahead of a potential pandemic.
The bank projects a near-term price target of $135,000 for Bitcoin, citing heavy ETF inflows and a break from historical post-halving patterns.
Regulators expedite review for ALTO-101, targeting a key aspect of schizophrenia with no currently approved treatments.
Major indices post gains with the S&P 500 touching a new high as investors anticipate potential monetary easing from the Federal Reserve.
With a potential market of 128 million in the U.S., analysts see blockbuster potential for the new presbyopia treatment.
Positive Phase 1 results for the company's epilepsy drug candidate are coupled with a significant financing deal that could dilute shares.
Tecentriq in combination with Zepzelca approved as a first-line maintenance treatment for extensive-stage small cell lung cancer, a significant advancement for a hard-to-treat cancer.
The approval covers a first-line maintenance treatment for an aggressive form of small cell lung cancer, a historically difficult-to-treat disease.